AIMS/HYPOTHESIS: Individual sulfonylureas (SUs) and metformin have, in some studies, been associated with unequal hypoglycaemic, cardiovascular and mortality risks when used as monotherapy in type 2 diabetes. We investigated the outcomes in patients treated with different combinations of SUs and insulin vs a combination of metformin and insulin in a retrospective nationwide study. METHODS: All Danish individuals using dual therapy with SU + insulin or metformin + insulin without prior myocardial infarction (MI) or stroke were followed from 1 January 1997 to 31 December 2009 in nationwide registries. Risks of all-cause mortality, cardiovascular death, hypoglycaemia and a composite endpoint of MI, stroke and cardiovascular death were compared. Rate ratios (RR) [95% CIs] were calculated using time-dependent multivariable Poisson regression analysis. RESULTS: A total of 11,081 patients used SU + insulin and 16,910 used metformin + insulin. Patients receiving metformin + insulin were younger and had less comorbidity and a longer history of glucose-lowering treatment. SU + insulin was associated with higher mortality rates compared with metformin + insulin (76-126 vs 23 per 1,000 person-years). In adjusted analyses, SU + insulin was associated with increased all-cause mortality (RR 1.81 [1.63, 2.01]), cardiovascular death (RR 1.35 [1.14, 1.60]) and the composite endpoint (RR 1.25 [1.09, 1.42]) compared with metformin + insulin. Hypoglycaemia was more frequent with SU + insulin than with metformin + insulin (17-23 vs six events per 1,000 person-years) and was associated with increased mortality (RR 2.13 [1.97, 2.37]). There were no significant differences in risk between individual SUs in combination with insulin. CONCLUSIONS/ INTERPRETATION: In combination with insulin, the use of SUs was associated with increased mortality compared with metformin. There were no significant risk differences between SUs.
AIMS/HYPOTHESIS: Individual sulfonylureas (SUs) and metformin have, in some studies, been associated with unequal hypoglycaemic, cardiovascular and mortality risks when used as monotherapy in type 2 diabetes. We investigated the outcomes in patients treated with different combinations of SUs and insulin vs a combination of metformin and insulin in a retrospective nationwide study. METHODS: All Danish individuals using dual therapy with SU + insulin or metformin + insulin without prior myocardial infarction (MI) or stroke were followed from 1 January 1997 to 31 December 2009 in nationwide registries. Risks of all-cause mortality, cardiovascular death, hypoglycaemia and a composite endpoint of MI, stroke and cardiovascular death were compared. Rate ratios (RR) [95% CIs] were calculated using time-dependent multivariable Poisson regression analysis. RESULTS: A total of 11,081 patients used SU + insulin and 16,910 used metformin + insulin. Patients receiving metformin + insulin were younger and had less comorbidity and a longer history of glucose-lowering treatment. SU + insulin was associated with higher mortality rates compared with metformin + insulin (76-126 vs 23 per 1,000 person-years). In adjusted analyses, SU + insulin was associated with increased all-cause mortality (RR 1.81 [1.63, 2.01]), cardiovascular death (RR 1.35 [1.14, 1.60]) and the composite endpoint (RR 1.25 [1.09, 1.42]) compared with metformin + insulin. Hypoglycaemia was more frequent with SU + insulin than with metformin + insulin (17-23 vs six events per 1,000 person-years) and was associated with increased mortality (RR 2.13 [1.97, 2.37]). There were no significant differences in risk between individual SUs in combination with insulin. CONCLUSIONS/ INTERPRETATION: In combination with insulin, the use of SUs was associated with increased mortality compared with metformin. There were no significant risk differences between SUs.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Azim S Gangji; Tali Cukierman; Hertzel C Gerstein; Charles H Goldsmith; Catherine M Clase Journal: Diabetes Care Date: 2007-02 Impact factor: 19.112
Authors: F Tomai; F Crea; A Gaspardone; F Versaci; R De Paulis; A Penta de Peppo; L Chiariello; P A Gioffrè Journal: Circulation Date: 1994-08 Impact factor: 29.690
Authors: Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin Journal: Ann Intern Med Date: 2012-11-06 Impact factor: 25.391
Authors: Sandra K Thygesen; Christian F Christiansen; Steffen Christensen; Timothy L Lash; Henrik T Sørensen Journal: BMC Med Res Methodol Date: 2011-05-28 Impact factor: 4.615
Authors: Ioanna Tzoulaki; Mariam Molokhia; Vasa Curcin; Mark P Little; Christopher J Millett; Anthea Ng; Robert I Hughes; Kamlesh Khunti; Martin R Wilkins; Azeem Majeed; Paul Elliott Journal: BMJ Date: 2009-12-03
Authors: James S Floyd; Kerri L Wiggins; Mark Christiansen; Sascha Dublin; William T Longstreth; Nicholas L Smith; Barbara McKnight; Susan R Heckbert; Noel S Weiss; Bruce M Psaty Journal: Pharmacoepidemiol Drug Saf Date: 2015-11-08 Impact factor: 2.890
Authors: S Ioacara; C Guja; O Georgescu; S Martin; A Sirbu; M Purcaru; S Fica Journal: Acta Endocrinol (Buchar) Date: 2017 Jul-Sep Impact factor: 0.877